Merck(US:MRK) Zhi Tong Cai Jing·2025-09-03 13:20Core Viewpoint - Merck (MRK.US) announced positive results from the Phase III CORALreef Lipids study for Enlicitide, a treatment for hypercholesterolemia, marking the largest Phase III study completed for this drug [1] Group 1: Study Results - The CORALreef Lipids study is the largest Phase III trial completed for Enlicitide, which has previously successfully completed two other Phase III studies [1] - Enlicitide (MK-0616) is an oral cyclic peptide PCSK9 inhibitor developed by Merck [1] Group 2: Mechanism of Action - PCSK9 (proprotein convertase subtilisin/kexin type 9) is primarily expressed in the liver and is a contributor to elevated levels of "bad cholesterol" LDL-C [1] - PCSK9 binds to receptors on liver cells responsible for clearing LDL-C, resulting in a significant portion of LDL-C being unable to be absorbed [1]